Use of early circulating tumour DNA dynamics in patients with stage III melanoma receiving neoadjuvant combination immunotherapy.
Wei Yen Chan(Melanoma Institute Australia), Helen Rizos(Macquarie University), Georgina V. Long(The University of Sydney), Ashleigh Stewart(The University of Sydney), Richard A. Scolyer(The University of Sydney), Christian U. Blank(The Netherlands Cancer Institute), Jenny Lee(Blacktown & Mount Druitt Hospital), Alexander M. Menzies(The University of Sydney), Maria Gonzalez(The University of Sydney), Russell J. Diefenbach(The University of Sydney)
Cited by 2
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k